Philip C. Mack

11.9k citations

234 papers · 6.8k indexed · 1 hit paper · h-index 44

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics

Papers in

Oncology 155
- Lung Cancer Research Studies 43
- Colorectal Cancer Treatments and Studies 40
- Cancer-related Molecular Pathways 21
- Cancer Immunotherapy and Biomarkers 15
Pulmonary and Respiratory Medicine 152
- Lung Cancer Treatments and Mutations 123
- Lung Cancer Diagnosis and Treatment 23

Co-authors: David R. Gandara Primo N. Lara Tianhong Li Paul H. Gumerlock Angela M. Davies Hsing‐Jien Kung Oliver Gautschi Karen Kelly
Journals: Journal of Clinical Oncology (73 papers)Clinical Lung Cancer (29 papers)Journal of Thoracic Oncology (25 papers)Clinical Cancer Research (9 papers)Lung Cancer (7 papers)
Partner nations: United States Canada Switzerland

In The Last Decade

Philip C. Mack

231 papers receiving 6.7k citations

Hit Papers

align trajectories log scale

The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients 2018 · 271 citations

Peers

Countries citing papers authored by Philip C. Mack

Since Specialization

Citations

This map shows the geographic impact of Philip C. Mack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip C. Mack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip C. Mack more than expected).

Fields of papers citing papers by Philip C. Mack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip C. Mack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip C. Mack. The network helps show where Philip C. Mack may publish in the future.

Co-authors

The 25 scholars most cited alongside Philip C. Mack, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip C. Mack Line = papers co-authored together Philip C. Mack links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400) Journal of Thoracic Oncology ·David Kozono, Xing Hua, Michael C. Wu, Khaled Tolba, Saiama N. Waqar, Konstantin H. Dragnev, Haiying Cheng, C.M. Plugge, Philip C. Mack, Jhanelle E. Gray, Karen Kelly, Hossein Borghaei, Roy S. Herbst, David R. Gandara, Mary W. Redman	2024	3
2	ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer Cancers ·Aakash Desai, C. Hjort, نیوشا صمدائیان, Marcelo Corassa, Philip C. Mack, Jhanelle E. Gray, Bruna Pellini	2024	18
3	Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042) Clinical Cancer Research ·Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, Y.M. Chen, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Topić Vučenović, Wallace Akerley, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly	2023	9
4	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403) Clinical Cancer Research ·Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara	2022	31
5	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) Journal for ImmunoTherapy of Cancer ·Natasha B. Leighl, Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William Irvin, Sreekanth Reddy, Jeffrey Crawford, Jeffrey D. Bradley, Thomas E. Stinchcombe, Suresh S. Ramalingam, Jieling Miao, Katherine Minichiello, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou, Karen Kelly, David R. Gandara	2021	38
6	Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions Molecular Cancer Therapeutics ·Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess, Jonathan P. Orme, Anna D. Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel O’Neill, Richard A. Ward, M. Raymond V. Finlay, Darren McKerrecher, Mingshan Cheng, Vladimír Pagáč, Rebekah A. Burich, James Keck, David R. Gandara, Philip C. Mack, Darren A.E. Cross	2018	85
7	The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients Clinical Cancer Research ·Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough, Stefanie Mortimer, James V. Vowles, Reza Bayat Mokhtari, David R. Gandara, Philip C. Mack, Justin I. Odegaard, Rebecca J. Nagy, Arthur M. Baca, Helmy Eltoukhy, Darya Chudova, Richard B. Lanman, AmirAli Talasaz Hit paper breakdown →	2018	271
8	Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 Cancer Treatment and Research Communications ·Primo N. Lara, Melissa Plets, Catherine M. Tangen, Erik Gertz, Nicholas J. Vogelzang, Maha Hussain, P. Twardowski, Mark Garzotto, J. Paul Monk, Michael A. Carducci, Amir Goldkorn, Philip C. Mack, Ian M. Thompson, Marta Van Loan, David I. Quinn	2018	4
9	DIVERGENT ACTIVITY OF AFATINIB (AFAT) AND CETUXIMAB (CET) IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF ACQUIRED ERLOTINIB RESISTANCE. Journal of Thoracic Oncology ·Philip C. Mack, Neal Goodwin, William Holland, Karen Kelly, Tianhong Li, Primo Lara, David R. Gandara	2013	2
10	Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non–Small-Cell Lung Cancer: Implications for Therapy Journal of Thoracic Oncology ·Martin Maus, Philip C. Mack, Stephanie H. Astrow, Craig Stephens, Gary Zeger, Peter Grimminger, Gennadi I Bessonov, Eric C. Huang, Tianhong Li, Primo N. Lara, Kathleen D. Danenberg, David R. Gandara	2013	22
11	Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536 Journal of Thoracic Oncology ·Edward S. Kim, James Moon, Roy S. Herbst, Mary W. Redman, Shaker R. Dakhil, Mario R. Velasco, Fred R. Hirsch, Philip C. Mack, Karen Kelly, John V. Heymach, David R. Gandara	2013	21
12	Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer Molecular Cancer Therapeutics ·Peter M. Wilson, Melissa J. LaBonte, Heinz‐Josef Lenz, Philip C. Mack, Robert D. Ladner	2011	45
13	Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial Clinical Lung Cancer ·Primo N. Lara, Jeff Longmate, Karen L. Reckamp, Barbara J. Gitlitz, Athanassios Argiris, Suresh S. Ramalingam, Chandra P. Belani, Philip C. Mack, Derick Lau, Sadegh Mansoubi, James R. Wright, Frances A. Shepherd, Natasha B. Leighl, David R. Gandara	2011	17
14	Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors Annals of Oncology ·Helen K. Chew, George Somlo, Philip C. Mack, Barbara J. Gitlitz, Regina Gandour‐Edwards, Sichen Lin, Hannah Linden, Deng Qiang-xian, Xiaowei Yang, Angela M. Davies	2011	14
15	Fibroblast Growth Factor Signaling in Non–Small-Cell Lung Cancer Clinical Lung Cancer ·Thomas J. Semrad, Philip C. Mack	2011	35
16	Regulation of Id1 Expression by Src: Implications for Targeting of the Bone Morphogenetic Protein Pathway in Cancer Cancer Research ·Oliver Gautschi, Clifford G. Tepper, Phillip R. Purnell, Yoshihiro Izumiya, Christopher P. Evans, Tim P. Green, Pierre Y. Desprez, Primo N. Lara, David R. Gandara, Philip C. Mack, Hsing-Jien Kung	2008	67
17	Aurora Kinase Inhibitors: A New Class of Targeted Drugs in Cancer Clinical Lung Cancer ·Oliver Gautschi, Philip C. Mack, Angela M. Davies, Primo N. Lara, David R. Gandara	2006	19
18	Enhancing the anticancer activity of paclitaxel through cyclin-dependent kinase inhibition Cancer Research ·Philip C. Mack, 宮曽根美香, Paul H. Gumerlock, David R. Gandara	2004	1
19	SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. PubMed ·Primo N. Lara, David I. Quinn, Kim Margolin, Frederick J. Meyers, Jeff Longmate, Paul Frankel, Philip C. Mack, D.A. Potapova, Peter J.M. Valk, K. W. Lee, Antoni BronisÅaw Przygienda, Theodore Wun, Robert C. Gosselin, Weijian Yuan, Paul H. Gumerlock, Heinz Josef Lenz, James H. Doroshow, David R. Gandara	2003	51
20	Apoptosis-Related Gene and Protein Expression in Human Lymphoma Xenografts (Raji) After Low Dose Rate Radiation Using ⁶⁷ Cu-2IT-BAT-Lym-1 Radioimmunotherapy Cancer Biotherapy and Radiopharmaceuticals ·Linda A. Kroger, Gerald L. DeNardo, Paul H. Gumerlock, Cheng Xiong, Domenico Trezza, Xu Shi, Philip C. Mack, 三浦尚, Sally J. DeNardo	2001	35

About Philip C. Mack

Philip C. Mack is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 234 papers that have together received 6.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (123 papers), Cancer Genomics and Diagnostics (62 papers), Lung Cancer Research Studies (43 papers), Colorectal Cancer Treatments and Studies (40 papers), Lung Cancer Diagnosis and Treatment (23 papers), Cancer-related Molecular Pathways (21 papers), Cancer therapeutics and mechanisms (18 papers) and Cancer Immunotherapy and Biomarkers (15 papers). The work is most often cited by research in Oncology (3.8k citations), Cancer Research (1.9k citations), Pulmonary and Respiratory Medicine (3.5k citations), Molecular Biology (2.9k citations) and Pathology and Forensic Medicine (633 citations). Philip C. Mack has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include David R. Gandara, Primo N. Lara, Tianhong Li, Paul H. Gumerlock, Angela M. Davies, Hsing‐Jien Kung, Oliver Gautschi, Karen Kelly, Mary W. Redman and Fred R. Hirsch. Their work appears in journals such as Journal of Clinical Oncology, Clinical Lung Cancer, Journal of Thoracic Oncology, Clinical Cancer Research and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact